Literature DB >> 24209969

Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse.

Erin M Goodwin1, Qing Zhong, Catherine S Abendroth, Lindsay K Ward-Kavanagh, Todd D Schell, Timothy K Cooper.   

Abstract

An 8-mo-old female transgenic adenocarcinoma of the mouse prostate (C57BL/6-Tg(TRAMP)8247Ng/J) mouse presented with abdominal distention, lethargy, and serosanguineous vaginal discharge. A large primary renal tumor with metastases to lung and liver was present at necropsy. The tumor was composed of poorly differentiated and crowded epithelial cells forming ducts, acini, and cribriform patterns, with comedonecrosis and frequent bizarre mitoses. Immunohistochemistry revealed that neoplastic cells expressed nuclear SV40 T antigen, confirming aberrant expression of the transgene. In addition, cells were positive for pancytokeratin and negative for synaptophysin and estrogen and progesterone receptors. This report details the first transgene-induced tumor in a female TRAMP mouse.

Entities:  

Mesh:

Year:  2013        PMID: 24209969      PMCID: PMC3750669     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  19 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  A transgenic mouse prostate cancer model.

Authors:  J R Gingrich; N M Greenberg
Journal:  Toxicol Pathol       Date:  1996 Jul-Aug       Impact factor: 1.902

3.  Monoclonal antibodies specific for simian virus 40 tumor antigens.

Authors:  E Harlow; L V Crawford; D C Pim; N M Williamson
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

4.  Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model.

Authors:  Y Tani; A Suttie; G P Flake; A Nyska; R R Maronpot
Journal:  Vet Pathol       Date:  2005-05       Impact factor: 2.221

5.  Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.

Authors:  S Kasper; P C Sheppard; Y Yan; N Pettigrew; A D Borowsky; G S Prins; J G Dodd; M L Duckworth; R J Matusik
Journal:  Lab Invest       Date:  1998-03       Impact factor: 5.662

6.  Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.

Authors:  I-Tien Yeh; Robert L Reddick; Addanki Pratap Kumar
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

7.  Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.

Authors:  Teresa Chiaverotti; Suzana S Couto; Annemarie Donjacour; Jian-Hua Mao; Hiroki Nagase; Robert D Cardiff; Gerald R Cunha; Allan Balmain
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

8.  Prostate cancer in a transgenic mouse.

Authors:  N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

9.  Contemporary prevalence of infectious agents in laboratory mice and rats.

Authors:  Kathleen R Pritchett-Corning; Janice Cosentino; Charles B Clifford
Journal:  Lab Anim       Date:  2008-11-17       Impact factor: 2.471

10.  Metastatic prostate cancer in a transgenic mouse.

Authors:  J R Gingrich; R J Barrios; R A Morton; B F Boyce; F J DeMayo; M J Finegold; R Angelopoulou; J M Rosen; N M Greenberg
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

View more
  1 in total

1.  Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.

Authors:  Eugene M Cozza; Timothy K Cooper; Lynn R Budgeon; Neil D Christensen; Todd D Schell
Journal:  Cancer Immunol Immunother       Date:  2014-11-19       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.